NEW YORK, NY–(Marketwired – Nov 29, 2017) – Tauriga Sciences, Inc. (OTC PINK: TAUG) (“Tauriga” or the “Company”) today announced that it has decided to move its corporate headquarters from Danbury, Connecticut to Midtown Manhattan in New York City. The effective date of this relocation will be December 1, 2017.
Tauriga is pleased to announce that the following address will serve as its new Corporate Headquarters:
Tauriga Sciences Inc.
Attn: Seth M. Shaw (Chief Executive Officer)
555 Madison Avenue, 5th Floor
New York NY 10022
The Company has entered into a 24 month lease for the above-mentioned address, commencing December 1, 2017 and will be paying exactly $1,010 per month for the term of the lease.
ABOUT TAURIGA SCIENCES, INC.
Tauriga Sciences, Inc. (OTC PINK: TAUG) is engaged in building life sciences company through the development, marketing, distribution and potential licensing of a broad array of products and technologies. The Company is presently focused on its upcoming contemplated launch of a Cupacu Butter based lip balm product branded under the name: Herman. The Company believes that one of its most important strengths is its access to and relationships with potentially substantial distribution systems and networks. The Company intends to capitalize on distribution opportunities and will continually update shareholders on such developments. Please visit the Corporate Website at www.tauriga.com
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.
The pipeline is a term that refers to what number of products – vaccines, steroids, immune gadget suppressants, aphrodisiacs (all beneath the overall heading of medicine) – are in numerous levels of research and development (r&d). It takes among 10 to fifteen years for a median drug to make it to pharmacy counters from a scientist’s notebook.
The principle motive the pipeline fails to waft freely, is that the meals and drug management (fda) has its personal shut-off valve on the way to defend purchasers from capsules that can have surprising side outcomes. The fda has very strict recommendations and assessments that a drug should pass earlier than it reaches store shelves; even after passing the exams, the fda reserves the proper to tug the drug en masse at any time.
An investor or a person tormented by a deadly sickness may additionally bemoan that the fda is an additional quandary on an already complex system. But, as purchasers, we need to respect the fact that it’s far due to the fda that we can take an aspirin while not having to fear about developing a 3rd arm. (to continue studying at the subject, see the united states of america and downs of biotechnology.)
Facebook page FOREXINVESTORS
NEXUS SOCIAL JADTECNIC
Click here for reuse options!